CardiaTec, a techbio company focused on decoding cardiovascular disease biology, has secured $6.5 million in seed funding. The new capital will be used to expand its platform and advance proprietary drug targets to the preclinical stage. This investment highlights the growing interest and need for innovative approaches in treating cardiovascular diseases, the leading cause of death worldwide.
CardiaTec’s latest funding round saw contributions from several prominent investors, including Montage Ventures, Continuum Health Ventures, Laidlaw Ventures, and APEX Ventures. Notable figures such as Dr. Maximilien Levesque and Naheed Kurji also participated as individual investors. Additionally, Dr. Joseph Lehár has joined the company’s scientific advisory board, bringing valuable expertise from his time at Owkin.
Computational Techniques and Multi-Omics Data
The company leverages computational methods to analyze multi-omics data, which includes information from the genome, proteome, epigenome, and transcriptome. These approaches enable CardiaTec to navigate the complex biology of cardiovascular diseases and identify novel therapeutic targets. By collaborating with 65 hospitals across the US and UK, CardiaTec is building the largest multi-omics dataset of human heart tissues.
Expert Perspectives and Future Goals
Raphael Peralta, CEO and co-founder, expressed optimism about the potential of multi-omic modeling in discovering new treatments:
“Modelling complex cardiovascular disease biology across multiple omic dimensions has immense potential in unlocking new therapeutic strategies that will challenge the current standard of care.”
Todd Kimmel from Montage Ventures added:
“CardiaTec is at the forefront of a new era in cardiovascular drug discovery. Their unique combination of the world’s largest multi-omics dataset from human cardiac tissues and advanced computational technology positions them to uncover novel drug targets for the world’s leading cause of death.”
Past reports have highlighted the stagnation in therapeutic innovation for cardiovascular diseases due to a limited understanding of the disease’s underlying biology. CardiaTec’s approach aims to address this gap by utilizing large-scale multi-omics data to identify more targeted therapies. In contrast to previous efforts that struggled with poor translation from clinical trials, CardiaTec’s strategy shows promise in overcoming these challenges.
Drawing on research conducted over the last decade, the company has brought together industry experts from leading organizations like Bristol Myers Squibb and Recursion Pharmaceuticals. This multidisciplinary team strengthens CardiaTec’s ability to innovate and progress in this critical area of healthcare.
CardiaTec is poised to make significant strides in cardiovascular research with its recent funding and innovative approach. Understanding and modeling the complex biology of cardiovascular diseases using multi-omics data will likely pave the way for new therapeutic strategies. With strong backing from industry leaders and investors, CardiaTec is well-positioned to challenge existing treatment paradigms and offer improved solutions for a global health issue.
